




Contact: Dr. E. Clif Burdette, Ph.D.
Location: Champaign, IL USA
Email: cliff@acousticmed.com
Tel: 217.239.0900
Facsimile: 217.355.4470



Company Profile

Industry Sector: Medical Devices

Company Overview: Acoustic MedSystems, Inc. (AMS) is focused on development of its ultrasonic technology for minimally invasive targeted therapy. Acoustic MedSystems, Inc. (AMS) was formed to commercialize its proprietary **ACOUST_xTM** technology (**A**pplicators with **C**ontrollable **O**utput of **U**ltrasound for **S**elective **T**reatment) for minimally invasive targeted thermal ablation of tumors and other soft-tissue diseases. The primary product development emphasis is for focal treatment of early stage prostate cancer, ablation of liver cancer, and treatment of uterine fibroids.

Target Market(s): Hospitals, Clinics, and Outpatient Centers Worldwide

Management

Leadership:

E. Clif Burdette, President and CEO
 Kenneth Hughes, Business Development Officer
 Chris J. Diederich, Chief Scientific Officer

Scientific Affiliates:

John Hopkins University - Center for Integrated Surgical Systems and Technology for disease therapy, Radiation Oncology, Computer Science

University of California at San Francisco – Radiation Oncology, Thermal Therapy Research Group

Brigham & Women’s Hospital – Harvard Medical School – Radiology

Advisors: G.L. Fichtinger, PhD, R.H. Taylor, PhD, T.L. DeWeese, MD, N. Fay, MD, K.J. Hughes, MBA, A. Jacoby, MD, D.L. Song, MD, D.J. Apfelberg, MD, and C. M. Tempany, MD

Key Value Drivers

Technology*: The ACOUST_x device consists primarily of a small applicator needle or catheter designed for insertion into a treatment site, providing a simple and minimally invasive surgical approach without the problems associated with conventional treatments, and is highly conformable to match the target volume. High-power ultrasound energy is emitted from the applicator and absorbed locally in the diseased tissue, producing thermal destruction of the target volume within a few minutes.

Competitive Advantage: The ACOUST_x technology can provide significant benefits and improvements over traditional surgical procedures, as well as over other minimally invasive thermal surgery technologies at significantly less cost than competitive methods. It has treatment potential for a wide range of soft-tissues (malignant and benign tumors, other soft tissue disorders) including prostate, breast, liver, uterus (fibroids), brain, lung, bladder, and colo-rectal diseases. ***The entire treatment can be performed as an outpatient procedure, typically using only local anesthesia, and the patient can return home the same day with minimal complications or side-effects.***

Plan & Strategy: Seeking private equity and/or a strategic partner

Product Development & Pipeline

